Metagenomi (NASDAQ: MGX) director exits as shareholders back board
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Metagenomi Therapeutics, Inc. reported that Brian C. Thomas, Ph.D. resigned from its board of directors effective June 9, 2026, and the company stated his resignation was not due to any disagreement over operations, policies or practices. On the same date, Metagenomi held its 2026 annual stockholder meeting by virtual webcast. A quorum was established with 19,116,207 shares present or represented by proxy out of 37,647,057 shares outstanding and entitled to vote as of the April 13, 2026 record date. Stockholders elected Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. as Class II directors to serve until the 2029 annual meeting, and ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 5.07
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding eligible to vote: 37,647,057 shares
Shares present at meeting: 19,116,207 shares
Votes for Eckhardt: 7,296,718 votes
+3 more
6 metrics
Shares outstanding eligible to vote
37,647,057 shares
Common stock outstanding and entitled to vote as of April 13, 2026
Shares present at meeting
19,116,207 shares
Shares present or represented by proxy at 2026 annual meeting (quorum)
Votes for Eckhardt
7,296,718 votes
For election of Class II director nominee Juergen Eckhardt, M.D., M.B.A.
Votes for Bjerkholt
8,251,289 votes
For election of Class II director nominee Eric Bjerkholt, M.B.A.
Votes for auditor ratification
18,483,295 votes
For ratifying PricewaterhouseCoopers LLP as 2026 independent auditor
Votes against auditor ratification
51,847 votes
Against ratifying PricewaterhouseCoopers LLP for fiscal year ending December 31, 2026
Key Terms
emerging growth company, quorum, broker non-votes, independent registered public accounting firm, +1 more
5 terms
emerging growth company regulatory
"Emerging growth company Item 5.02."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
quorum regulatory
"thus establishing a quorum for the transaction of business at the Annual Meeting."
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
broker non-votes financial
"1,436,882 | | 10,382,607 Eric Bjerkholt, M.B.A. | | 8,251,289 | | 482,311 | | 10,382,607"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
proxy statement regulatory
"Proxies were solicited pursuant to the Company’s definitive proxy statement"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
FAQ
What board change did Metagenomi Therapeutics (MGX) disclose in this 8-K?
Metagenomi reported that director Brian C. Thomas, Ph.D. resigned from the board effective June 9, 2026. The company stated his resignation was not due to any disagreement over its operations, policies or practices, and thanked him for his service and contributions.
Which directors were elected at Metagenomi’s 2026 annual meeting and how long will they serve?
Stockholders elected Juergen Eckhardt, M.D., M.B.A. and Eric Bjerkholt, M.B.A. as Class II directors. They will serve until Metagenomi’s 2029 annual meeting and until their successors are duly elected and qualified, or until earlier death, resignation or removal under company governance.
Did Metagenomi (MGX) stockholders ratify the company’s independent auditor for 2026?
Stockholders ratified PricewaterhouseCoopers LLP as Metagenomi’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received 18,483,295 votes for, 51,847 against, and 581,065 abstentions, confirming continued engagement of the same audit firm.
What were the vote totals for Metagenomi director nominee Juergen Eckhardt?
Director nominee Juergen Eckhardt, M.D., M.B.A. received 7,296,718 votes for election and 1,436,882 votes withheld, with 10,382,607 broker non-votes. These results were sufficient for his election as a Class II director through Metagenomi’s 2029 annual stockholder meeting.